NCT03261635View on ClinicalTrials.gov

Ranibizumab Plus Indomethacin

PHASE4CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

January 7, 2016

Primary Completion Date

December 7, 2016

Study Completion Date

July 25, 2017

Conditions
Macular Edema
Interventions
DRUG

Ranibizumab Injection

patients received monthly 0.5 mg ranibizumab intravitreal injections for 3 months, after which monthly injections were administered pro re nata

DRUG

Indomethacin

patients self-administered one drop of indomethacin 0.5% eye drops three times a day for 12 months

All Listed Sponsors
lead

Università degli Studi di Brescia

OTHER

NCT03261635 - Ranibizumab Plus Indomethacin | Biotech Hunter | Biotech Hunter